Nektar Therapeutics announced the peer-reviewed publication of positive Phase 2b data for rezpegaldesleukin in atopic dermatitis. The study met all primary and key secondary endpoints, supporting the drug's continued development and validating its T-reg modulation mechanism.
Nektar Therapeutics has published peer-reviewed data from the 16-week induction period of its Phase 2b REZOLVE-AD study for rezpegaldesleukin in atopic dermatitis. The key takeaway is that the study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS, vIGA-AD, and BSA, for the 24 µg/kg q2w dose. This is significant because it validates the drug's efficacy and its novel T-reg modulation mechanism, which is the first large, placebo-controlled trial to support this approach for chronic inflammatory disease. This positive data supports the ongoing Phase 3 ZENITH AD clinical program, reducing clinical development risk and potentially accelerating future regulatory approvals. For traders, this represents a strong positive catalyst for NKTR in the short term due to de-risking the pipeline, and a long-term opportunity if the Phase 3 trials continue to be successful, potentially leading to a new blockbuster drug in the atopic dermatitis market.